Researchers recently conducted a systematic review and meta-analysis to examine whether leukocytosis is a risk factor for thrombosis in patients with myeloproliferative neoplasms.
Researchers recently conducted a systematic review and meta-analysis of articles published in the last 12 years to examine whether leukocytosis is a risk factor for thrombosis in patients with myeloproliferative neoplasms, predominantly in polycythemia vera (PV) and essential thrombocythemia (ET).
Previously, leukocytosis has not been formally included in risk models and prognostic scores. There are inconsistencies in the definition of leukocytosis, a lack of a clear cutoff value for white blood cell (WBC) counts, and heterogeneity in methods for its assessment, the researchers said.
In addition, past studies never specifically set out to assess the role of leukocytosis; as a result, the evidence that is available is inconclusive, since previous studies are highly heterogeneous in terms of size, statistical power, and duration of follow-up and exposure.
In this review, out of 515 articles screened, 41 were included in the analysis, comprising a pool of more than 30,000 patients. The primary outcome was a major thrombotic event, such as fatal or nonfatal myocardial infarction, stroke, transient ischemic attack, peripheral and visceral thromboembolism, or venous event (deep vein thrombosis, pulmonary embolism, cerebral venous sinus thrombosis, splanchnic circulation thrombosis) associated with leukocyte count after the diagnosis of ET or PV.
Secondary outcomes were defined as major bleeding events, hematologic transformations and/or solid neoplasms, and overall mortality.
The relative risk (RR) of thrombosis in the presence of leukocytosis was 1.59 (95% CI, 1.40-1.80), mainly accounted for by ET (RR, 1.65; 95% CI, 1.43-1.91) and arterial thrombosis (RR, 1.45; 95% CI, 1.13-1.86) subgroups.
The primary results were confirmed by a sensitivity analyses considering recurrent events as well as white blood cell estimates adjusted or unadjusted for confounding factors. In addition, the pooled RR of studies that tested white blood cell counts in time-dependent models suggested a causative effect of leukocytes in the development of thrombosis.
The effect of leukocytosis on bleeding (RR, 1.87; 95% CI, 1.26-2.77) and death (RR, 1.89; 95% CI, 1.59-2.23) was confirmed.
However, conclusions on hematologic evolutions and solid tumors were uncertain, and the effect was not significant in venous thrombosis alone. The researchers said future studies should examine individual patient data in a large collective archive of homogeneous patients.
Reference
Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019;3(11):1729-1737; doi:10.1182/bloodadvances.2019000211.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More